Discover 522 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 522
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
for
Transthyretin Amyloidosis With Cardiomyopathy
Location: Memphis TN, St Louis MO, Kansas City KS, Dallas TX,
Sponsor: Alnylam Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07358078
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Bartlett TN, Mount Juliet TN, Tennessee City TN,
Sponsor: Olema Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07085767
Phase3, Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
for
Lymphoid Malignancies
Location: Memphis TN, Louisville KY, Dallas TX, Chicago IL,
Sponsor: AVM Biotechnology Inc
Sex: All
Age: 12 - 70+
Code: NCT04329728
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
for
Cancer Weight Loss
Location: Memphis TN, Atlanta GA, Oklahoma City OK, Wichita KS,
Sponsor: Endevica Bio
Sex: All
Age: 18+
Code: NCT06937177
Phase2, Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Location: Memphis TN, Little Rock AR, Birmingham AL, St Louis MO,
Sponsor: BrioHealth Solutions, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06310031
Recruiting
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
Location: Memphis TN, St Louis MO, Athens GA, Dallas TX,
Sponsor: Turning Point Therapeutics, Inc.
Sex: All
Age: 12+
Code: NCT03093116
Phase1, Phase2, Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
for
Triple-Negative Breast Cancer
Location: Memphis TN, Germantown TN, Nashville TN, Jackson MS,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06393374
Phase3, Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
for
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma,
Location: Memphis TN, Nashville TN, Indianapolis IN, Iowa City IA,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT06324357
Phase1, Phase2, Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Location: Memphis TN, Carterville IL, Birmingham AL,
Sponsor: Tempus AI
Sex: All
Age: 18+
Code: NCT05236114
Recruiting
Immunonutrition in Ulcerative Colitis
for
Ulcerative Colitis
Location: Memphis TN
Sponsor: Baptist Memorial Health Care Corporation
Sex: All
Age: 18+
Code: NCT03594708
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
for
Chronic Graft-versus-host-disease
Location: Memphis TN, Birmingham AL, Atlanta GA, Kansas City KS,
Sponsor: Incyte Corporation
Sex: All
Age: 12+
Code: NCT06585774
Phase3, Recruiting
Temsirolimus as Second-line Therapy in HCC
for
Unresectable or Metastatic Hepatocellular Carcinoma
Location: Memphis TN
Sponsor: University of Tennessee Cancer Institute
Sex: All
Age: 18+
Code: NCT01567930
Phase2, Recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)